Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, multicenter, phase II study to investigate the efficacy
and safety of Ensartinib plus Bevacizumab in metastatic anaplastic lymphoma kinase
(ALK)-rearranged Non-Small Cell Lung Cancer (NSCLC) with TP53 mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Handan Central Hospital Harbin Medical University Hebei Medical University Fourth Hospital Huai'an First People's Hospital Jiangsu Cancer Institute & Hospital Liaoning Cancer Hospital & Institute Second Affiliated Hospital, School of Medicine, Zhejiang University Shenyang Chest Hospital The First Affiliated Hospital of Soochow University The First Affiliated Hospital with Nanjing Medical University Wuhan Union Hospital, China